Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Jiménez JL, Bishton M, Dholaria B, Mengarelli A, Phillips TJ, Sungala N, Musuraca G, Sheehy O, Van Den Neste E, Odera M, Miao L, Gold DP, Ghalie RG, Zinzani PL. Zelenetz AD, et al. Among authors: collins gp. Hemasphere. 2024 Aug 6;8(8):e138. doi: 10.1002/hem3.138. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39108321 Free PMC article.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
Eyre TA, Linton KM, Rohman P, Kothari J, Cwynarski K, Ardeshna K, Bailey C, Osborne WL, Rowntree C, Eden D, Shankara P, Eyre DW, Jasani P, Chaidos A, Collins GP, Hatton CS. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2016 Jun;173(6):896-904. doi: 10.1111/bjh.14021. Epub 2016 Mar 9. Br J Haematol. 2016. PMID: 26956150 Free article.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Eyre TA, Phillips EH, Linton KM, Arumainathan A, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP. Eyre TA, et al. Among authors: collins gp. Br J Haematol. 2017 Nov;179(3):471-479. doi: 10.1111/bjh.14898. Epub 2017 Aug 31. Br J Haematol. 2017. PMID: 28857136 Free article.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. Among authors: collins gp. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP. Eyre TA, et al. Among authors: collins gp. Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9. Hematol Oncol. 2019. PMID: 31385336 Clinical Trial.
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J. Gibb A, et al. Among authors: collins gp. Br J Haematol. 2021 Apr;193(1):63-71. doi: 10.1111/bjh.17073. Epub 2020 Sep 14. Br J Haematol. 2021. PMID: 32926420 Free article. Clinical Trial.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: collins gp. Blood Adv. 2021 Apr 27;5(8):2229-2236. doi: 10.1182/bloodadvances.2021004286. Blood Adv. 2021. PMID: 33890978 Free PMC article.
197 results